Tech Center 1600 • Art Units: 1647
This examiner grants 67% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18201572 | PM21 PARTICLES TO IMPROVE BONE MARROW HOMING OF NK CELLS | Non-Final OA | Research Institute at Nationwide Children's Hospital |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17797666 | IL-10 AND USES THEREOF | Non-Final OA | Bristol-Myers Squibb Company |
| 18924824 | MULTICOMPONENT CHEMICAL COMPOSITION OF A PEPTIDE-BASED NEOANTIGEN VACCINE | Non-Final OA | AMAZON TECHNOLOGIES, INC |
| 18964025 | DIMERIC IMMUNOCONJUGATES FOR USE IN TREATING CANCERS AND METHODS OF USE | Final Rejection | Medicovestor, Inc. |
| 18096349 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18040888 | METHODS OF TREATING MALIGNANT GLIOBLASTOMA | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17998198 | TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB | Final Rejection | Janssen Pharmaceutica NV |
| 17085040 | Pharmaceutical Composition for Cancer Treatment | Non-Final OA | Osaka University |
| 17422309 | SELF-ASSEMBLED PEPTIDE NANOPARTICLE AND USE THEREOF | Final Rejection | THE METHODIST HOSPITAL |
| 17775561 | ANTI-GUCY2C VACCINES AND VACCINATION | Non-Final OA | THOMAS JEFFERSON UNIVERSITY |
| 18320653 | Methods for Detecting and Treating Irritable Bowel Syndrome | Non-Final OA | Cedars-Sinai Medical Center |
| 18325860 | METHOD OF TREATMENT OF A TUMOR WITH IL-8 ANTIBODY | Non-Final OA | NantBio, Inc. |
| 18302364 | TARGETED THERAPEUTIC AGENTS AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 18318588 | USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | The U.S.A. as Represented by the Secretary, Department of Health and Human Services |
| 18322542 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | Non-Final OA | BEIGENE SWITZERLAND GMBH |
| 17917923 | METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN | Non-Final OA | Juno Therapeutics, Inc. |
| 18042068 | METHODS OF TREATING CANCER | Non-Final OA | LONZA SALES AG |
| 18027993 | DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | Bio-Thera Solutions, Ltd. |
| 18297064 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17915990 | METHODS AND COMPOSITIONS FOR MODULATING LIPID STORAGE IN ADIPOSE TISSUE | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18249023 | PAN-RAS mRNA CANCER VACCINES | Non-Final OA | RNAimmune, Inc. |
| 18298021 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | Non-Final OA | MOONSHOT PHARMA LLC |
| 18296710 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Non-Final OA | Synthorx, Inc. |
| 18030426 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS | Non-Final OA | AOA Dx |
| 17928806 | INORGANIC NANOPARTICLE-BASED VACCINE COMPOSITIONS FOR CANCER TREATMENT | Non-Final OA | Universidad de la Habana |
| 18043923 | MODIFIED MYCOBACTERIUM BOVIS VACCINES | Non-Final OA | Valo Therapeutics Oy |
| 17780758 | THERAPEUTIC DRUG FOR CARCINOMATOUS PERITONITIS | Final Rejection | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY |
| 17783866 | PERSONALIZED TUMOR VACCINE AND USE THEREOF FOR CANCER IMMUNOTHERAPY | Final Rejection | University of South Bohemia in Ceske Budejovice |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy